To include your compound in the COVID-19 Resource Center, submit it here.

EMA's PRAC limits use of MS drug Zinbryta due to liver safety concerns

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) announced provisional restrictions on multiple sclerosis drug Zinbryta daclizumab (DAC HYP) that will limit

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE